Regeneron Libtayo combo fails in melanoma trial against Keytruda
Regeneron disclosed a late-stage trial evaluating a Libtayo-based combination for melanoma failed to meet its endpoints when compared with Merck’s Keytruda, sparking investor scrutiny of Regeneron’s cancer-immunotherapy program.